Open Access

REVIEW

MEIR DJALDETTI^*
Oncology Research, Vol.32, No.9, pp. 1389-1399, 2024, DOI:10.32604/or.2024.049745 - 23 August 2024
Abstract Resveratrol (RSV), the primary polyphenol found in grapes, has been revealed to have anti-inflammatory properties by reducing the capacity of the peripheral blood mononuclear cells to produce pro-inflammatory cytokines, including IL-1β, IL-6, IL-1ra and TNFα. Considering the close association between chronic inflammation and cancer development, RSV’s immunomodulatory properties are one way by which the polyphenol may inhibit cancer initiation, proliferation, neovascularization, and migration. Resveratrol influences the generation of microtumor environment which is one of the key factors in cancer progress. In addition to immunomodulation, RSV inhibits cancer development by expressing anti-oxidant effects, causing cell cycle… More >

Graphic Abstract

View

1096

Download

279

Open Access

ARTICLE

TATIANA KURILO^*, REBECCA D. PENTZ
Oncology Research, Vol.32, No.9, pp. 1401-1406, 2024, DOI:10.32604/or.2024.050266 - 23 August 2024
Abstract Objectives: Rural patients have poor cancer outcomes and clinical trial (CT) enrollment compared to urban patients due to attitudinal, awareness, and healthcare access differential. Knowledge of cancer survival disparities and CT enrollment is important for designing interventions and innovative approaches to address the stated barriers. The study explores the potential disparities in cancer survival rates and clinical trial enrollments in rural and urban breast and lung cancer patients. Our hypotheses are that for both cancer types, urban cancer patients will have longer 5-year survival rates and higher enrollment rates in clinical trials than those in… More >

View

1200

Download

308

Open Access

ARTICLE

ROSSANA RONCATO^1,2, JERRY POLESEL³, FEDERICA TOSI^4,5,*, ELENA PERUZZI^1,*, ERIKA BRUGUGNOLI⁶, CLAUDIA LAURIA PANTANO⁷, MARIA FURFARO⁸, FILIPPO DI GIROLAMO^9,10, ALESSANDRO NANI¹¹, ARIANNA PANI⁴, NOEMI MILAN¹, ELENA DE MATTIA¹, ANDREA SARTORE-BIANCHI^4,5, ERIKA CECCHIN¹
Oncology Research, Vol.32, No.9, pp. 1407-1422, 2024, DOI:10.32604/or.2024.049181 - 23 August 2024
Abstract Objectives: Treatment of metastatic colorectal cancer (mCRC) includes resection of liver metastases (LM), however, no validated biomarker identifies patients most likely to benefit from this procedure. This meta-analysis aimed to assess the impact of the most relevant molecular alterations in cancer-related genes of CRC (i.e., RAS, BRAF, SMAD4, PIK3CA) as prognostic markers of survival and disease recurrence in patients with mCRC surgically treated by LM resection. Methods: A systematic literature review was performed to identify studies reporting data regarding survival and/or recurrence in patients that underwent complete liver resection for CRC LM, stratified according to… More >

Graphic Abstract

View

1390

Download

261

Open Access

VIEWPOINT

STEPHEN E. LANGABEER^*
Oncology Research, Vol.32, No.9, pp. 1423-1427, 2024, DOI:10.32604/or.2024.051218 - 23 August 2024
Abstract Hairy cell leukemia (HCL) is an uncommon mature B-cell malignancy characterized by a typical morphology, immunophenotype, and clinical profile. The vast majority of HCL patients harbor the canonical BRAF V600E mutation which has become a rationalized target of the subsequently deregulated RAS-RAF-MEK-MAPK signaling pathway in HCL patients who have relapsed or who are refractory to front-line therapy. However, several HCL patients with a classical phenotype display non-canonical BRAF mutations or rearrangements. These include sequence variants within alternative exons and an oncogenic fusion with the IGH gene. Care must be taken in the molecular diagnostic work-up of patients More >

View

913

Download

237

Open Access

ARTICLE

YUZHI LIU^1,#, EVELYNE BISCHOF^2,#, ZHIQIN CHEN¹, JIAHUAN ZHOU³, BEI ZHANG⁴, DING ZHANG⁴, YONG GAO^1,*, MING QUAN^1,*
Oncology Research, Vol.32, No.9, pp. 1429-1438, 2024, DOI:10.32604/or.2024.047309 - 23 August 2024
Abstract Objectives: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have demonstrated potential benefits for metastatic colorectal cancer (mCRC) patients with HER2 amplification, but are not satisfactory in cases of HER2 mutant CRCs. Methods: Consequently, further elucidation of amplifications and somatic mutations in erythroblastic oncogene B-2 (ERBB2) is imperative. Comprehensive genomic profiling was conducted on 2454 Chinese CRC cases to evaluate genomic alterations in 733 cancer-related genes, tumor mutational burden, microsatellite instability, and programmed death ligand 1 (PD-L1) expression. Results: Among 2454 CRC patients, 85 cases (3.46%) exhibited ERBB2 amplification, and 55 cases (2.24%) carried ERBB2 mutation.… More >

Graphic Abstract

View

1308

Download

261

Open Access

ARTICLE

PEILING WU^#, LIFANG ZHAO^#, HONGYAN ZHANG, YUEYAN LOU, DONGFANG CHEN, SHAN XUE, XUEQING LIU^*, HANDONG JIANG^*
Oncology Research, Vol.32, No.9, pp. 1439-1452, 2024, DOI:10.32604/or.2024.047490 - 23 August 2024
Abstract Objectives: The pro-oncogenic effects of NCAPD2 have been extensively studied across various tumor types; however, its precise role within the context of lung adenocarcinoma (LUAD) remains elusive. This study aims to elucidate the biological functions of NCAPD2 in LUAD and unravel the underlying mechanistic pathways. Methods: Utilizing bioinformatics methodologies, we explored the differential expression of NCAPD2 between normal and tumor samples, along with its correlations with clinical-pathological characteristics, survival prognosis, and immune infiltration. Results: In the TCGA-LUAD dataset, tumor samples demonstrated significantly elevated levels of NCAPD2 expression compared to normal samples (p < 0.001). Clinically, higher… More >

View

1271

Download

286

Open Access

ARTICLE

ZIYONG LIU^1,#, TAO MA^1,#, JINFANG LI², WEI REN^1,*, ZHIXIN ZHANG^1,*
Oncology Research, Vol.32, No.9, pp. 1453-1465, 2024, DOI:10.32604/or.2024.048315 - 23 August 2024
Abstract Background: Interleukin 13 receptor subunit alpha 2 (IL13RA2) plays an essential role in the progression of many cancers. However, the role of IL13RA2 in infantile haemangioma (IH) is still unknown. Materials and Methods: IL13RA2 expression in IH tissues was analyzed using western blot, qRT-PCR, and immunofluorescence. The role of IL13RA2 in haemangioma-derived endothelial cells (HemECs) was determined following knockdown or overexpression of IL13RA2 using CCK-8, colony formation, apoptosis, wound healing, tubule formation, Transwell, and western blot. Results: IL13RA2 expression was upregulated in IH tissues. IL13RA2 overexpression promoted proliferation, migration, and invasion of HemECs and induced glycolysis, More >

View

1178

Download

250

Open Access

ARTICLE

LIANG HE^1,2, WEI HAN^1,3, KAI YUE¹, XUDONG WANG^1,*
Oncology Research, Vol.32, No.9, pp. 1467-1478, 2024, DOI:10.32604/or.2024.047382 - 23 August 2024
Abstract Objectives: Thyroid cancer (THCA) is the most common malignant tumor in endocrine system and the incidence has been increasing worldwide. And the number of patients dying from THCA has also gradually risen because the incidence continues to increase, so the mechanisms related to effective targets is necessary to improve the survival. This study was to preliminarily investigate the effects of the COL4A2 gene on the regulation of thyroid cancer (THCA) cell proliferation and the associated pathways. Methods: Bioinformatics analysis revealed that COL4A2 was closely associated with cancer development. COL4A2 expression in THCA tissues was analyzed… More >

View

1076

Download

246

Open Access

REVIEW

ZHENGYI WANG^1,*, LIANG ZHOU¹, XIAOYING WU²
Oncology Research, Vol.32, No.9, pp. 1479-1516, 2024, DOI:10.32604/or.2024.048564 - 23 August 2024
Abstract Chimeric antigen receptor T-cesll therapy (CAR–T) has achieved groundbreaking advancements in clinical application, ushering in a new era for innovative cancer treatment. However, the challenges associated with implementing this novel targeted cell therapy are increasingly significant. Particularly in the clinical management of solid tumors, obstacles such as the immunosuppressive effects of the tumor microenvironment, limited local tumor infiltration capability of CAR–T cells, heterogeneity of tumor targeting antigens, uncertainties surrounding CAR–T quality, control, and clinical adverse reactions have contributed to increased drug resistance and decreased compliance in tumor therapy. These factors have significantly impeded the widespread More >

Graphic Abstract

View

1265

Download

258

Open Access

CORRECTION

CHENGLIN QIN^1,2, LINFANG JIN^1,3, JIA LI^1,4, WENZHANG ZHA², HUIMING DING², XIAORONG LIU^1,5, XUN ZHU^1,*
Oncology Research, Vol.32, No.9, pp. 1517-1522, 2024, DOI:10.32604/or.2024.051893 - 23 August 2024
Abstract This article has no abstract. More >

View

427

Download

194

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.9, pp. 1523-1523, 2024, DOI:10.32604/or.2024.056118 - 23 August 2024
Abstract This article has no abstract. More >

View

516

Download

195

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.9, pp. 1525-1525, 2024, DOI:10.32604/or.2024.056119 - 23 August 2024
Abstract This article has no abstract. More >

View

508

Download

213

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.9, pp. 1527-1527, 2024, DOI:10.32604/or.2024.056120 - 23 August 2024
Abstract This article has no abstract. More >

View

470

Download

185

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.9, pp. 1529-1529, 2024, DOI:10.32604/or.2024.056121 - 23 August 2024
Abstract This article has no abstract. More >

View

467

Download

191

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.9, pp. 1531-1531, 2024, DOI:10.32604/or.2024.056122 - 23 August 2024
Abstract This article has no abstract. More >

View

516

Download

183

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.9, pp. 1533-1533, 2024, DOI:10.32604/or.2024.056123 - 23 August 2024
Abstract This article has no abstract. More >

View

471

Download

174

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.9, pp. 1535-1535, 2024, DOI:10.32604/or.2024.056124 - 23 August 2024
Abstract This article has no abstract. More >

View

479

Download

197

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.9, pp. 1537-1537, 2024, DOI:10.32604/or.2024.056125 - 23 August 2024
Abstract This article has no abstract. More >

View

523

Download

191

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.9, pp. 1539-1539, 2024, DOI:10.32604/or.2024.056126 - 23 August 2024
Abstract This article has no abstract. More >

View

523

Download

177

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.9, pp. 1541-1541, 2024, DOI:10.32604/or.2024.056127 - 23 August 2024
Abstract This article has no abstract. More >

View

523

Download

211